• Research Technician I-II, Antibody Technology Resource

    Job ID
    13193
    Type
    Regular Full-Time
    Company
    Fred Hutchinson Cancer Research Center
    Location
    US-WA-Seattle
    Category
    Laboratory Research Sciences
  • Overview

    Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.

    Responsibilities

    The Fred Hutch Antibody Technology lab is recognized internationally as a one of the most technically advanced academic groups in monoclonal antibody discovery.  In addition to developing diagnostic and therapeutic antibodies for Fred Hutch research programs, the team coordinates external collaborations with academic and industrial clients on approximately 40 novel antibody discovery campaigns annually. Over the past four years the lab has integrated over $2.5M in laboratory automation and high-throughput screening technology for monoclonal antibody discovery. 

     

    The team is currently seeking a highly motivated individual to fill a Research Technician I or II position depending on years of education and experience.  The position may be ideal for a recent BA/BS, MA, or PhD graduate seeking unique experience in high-throughput screening of biologics, laboratory automation, and molecular engineering of antibody compositions for potential diagnostics and therapeutics.  The ability to work independently on multiple projects simultaneously is essential.

     

    Specific responsibilities include:

    • Scheduling and tracking multiple projects.
    • Comfortable working with and programming complex automated instrumentation.
    • Molecular biology knowledge is essential and experience desired.
    • Comfortable with IACUC approved use of mice, rats, and rabbits for the generation of novel antibody compositions.  Experience with handling mice a plus. 

    Qualifications

    The successful candidate must be highly motivated, reliable, and independently productive with a BA/BS, MS, or PhD degree in a scientific discipline (biology, chemistry, engineering, or computer science). Some hands-on laboratory experience is preferred but is not essential as the work is specialized. Knowledge of specialized software applications (Tecan EVOWare, ClonePix Fusion, IntelliCyt ForeCyt, UNICORN, Thermo Momentum, Geneious, Liquid Planner) is a plus, however having a strong interest to master these applications is essential.    

     

    Please include a cover letter with your application, detailing your interest and suitability for this position.

    Our Commitment to Diversity

    We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We are proud to be an Equal Opportunity and VEVRAA Employer. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at escmail@fredhutch.org or by calling 206-667-4700.

    Options

    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed